Reduced inotropic support after aprotinin therapy during pediatric cardiac operations

Annals of Thoracic Surgery

Volumn 67, Issue 1, 1999, Pages 173-176

  Wippermann, Carl F ^a,b   Schmid, Franz X ^a   Eberle, Balthasar ^a   Huth, Ralf G ^a   Kampmann, Christoph ^a   Schranz, Dietmar ^a   Oelert, Helmut ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; APROTININ; ENOXIMONE; FUROSEMIDE; PLACEBO;

ADOLESCENT; ARTICLE; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HEART PROTECTION; HEART SURGERY; HEMODYNAMICS; HUMAN; INFANT; INOTROPISM; INTENSIVE CARE; MALE; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; APROTININ; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ENOXIMONE; FEMALE; HEART DEFECTS, CONGENITAL; HEMODYNAMIC PROCESSES; HEMOSTATICS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PHOSPHODIESTERASE INHIBITORS;

EID: 0033031465     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00974-6     Document Type: Article

References (25)

1. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-20.
2. Van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
3. Wendel HP, Heller W, Michel J, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995;109:1164-72.
4. Gurevitch J, Barak J, Hochhauser E, Paz Y, Yakirevich V. Aprotinin improves myocardial recovery after ischemia and reperfusion. Effects of the drug on isolated rat hearts. J Thorac Cardiovasc Surg 1994;108:109-18.
5. Chang AC, Atz AM, Wernovsky G, Burke RP, Wessel DL. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 1995;23:107-14.
6. Kuraoka S, Orita H, Watanabe T, et al. Effects of combined aprotinin and prostagrandin E1 therapy on aortic arch replacement. Kyobu Geka 1995;48:198-201.
7. Broche W, Suarez AR, Olembe E, et al. Aprotinin effects related to oxidative stress in cardiosurgery with mechanical cardiorespiratory support (CMCS). Ann N Y Acad Sci 1996;793:521-4.
8. Dwenger A, Remmers D, Grotz M, et al. Aprotinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model. Eur J Clin Chem Clin Biochem 1996;34:207-14.
9. Sultan I, Sunamori M, Suzuki A. Heart preservation: analysis of cardioprotective infusate characteristics. Membrane stabilization, calcium antagonism, and protease inhibition on myocardial viability: a biochemical, ultrastructural, functional study. J Heart Lung Transplant 1992;11:607-18.
10. Bukhari EA, Krukenkamp IB, Burns PG, et al. Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann Thorac Surg 1995;60:307-10.
11. Sunamori M, Sultan I, Suzuki A. Effect of aprotinin to improve myocardial viability in myocardial preservation followed by reperfusion. Ann Thorac Surg 1991;52:971-8.
12. Hess ML, Kukreja RC. Free radicals, calcium homeostasis, heat shock proteins, and myocardial stunning. Ann Thorac Surg 1995;60:760-6.
13. Rao PS, Palazzo RS, Bocchieri KA, et al. Aprotinin protects against myocardial and oxidant formation and endothelial cell damage during open heart surgery. Ann N Y Acad Sci 1996;793:514-6.
14. Horwitz LD, Leff JA. Catalase and hydrogen peroxide cytotoxicity in cultured cardiac myocytes. J Mol Cell Cardiol 1995;27:909-15.
15. Hoffstein S, Weissmann G, Fox AC. Lysosomes in myocardial infarction: studies by means of cytochemistry and subcellular fractionation, with observations on the effects of methylprednisolone. Circulation 1976;53:34-40.
16. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.
17. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
18. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;110:1658-62.
19. Diego RP, Mihalakakos PJ, Hexum TD, Hill GE. Methylprednisolone and full-dose aprotinin reduce reperfusion injury after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:29-31.
20. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-67.
21. Schutzer KM, Lindholm E, Haglund U, Falk A. Cardiopulmonary function as related to thromboxane a2 synthesis in experimental septic shock. Circ Shock 1988;26:27-40.
22. Ruvolo G, Speziale G, Greco E, et al. Nitric oxide release during hypothermic versus normothermic cardiopulmonary bypass. Eur J Cardiothorac Surg 1995;9:651-4.
23. Matheis G, Sherman MP, Buckberg GD, Haybron DM, Young HH, Ignarro LJ. Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol 1992; 262:H616-20.
24. Hill GE, Springall DR, Robbins RA. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery 1997;121:449-55.
25. Cumming AD, Nimmo GR, Craig KJ, McGilchrist A, Hayes PC. Vasoactive effects of aprotinin. Agents Actions 1992; 38(Suppl):211-8.